

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
 NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS 4 Apr 09 ZDB will be removed from STN
 NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
 NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
 NEWS 9 Jun 03 New e-mail delivery for search results now available
 NEWS 10 Jun 10 MEDLINE Reload
 NEWS 11 Jun 10 PCTFULL has been reloaded
 NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
 NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
 saved answer sets no longer valid
 NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
 NEWS 15 Jul 30 NETFIRST to be removed from STN
 NEWS 16 Aug 08 CANCERLIT reload
 NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18 Aug 08 NTIS has been reloaded and enhanced
 NEWS 19 Aug 09 JAPIO to be reloaded August 18, 2002

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
 CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
 AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:19:50 ON 19 AUG 2002

=> fil reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:20:06 ON 19 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 AUG 2002 HIGHEST RN 444143-26-4
DICTIONARY FILE UPDATES: 16 AUG 2002 HIGHEST RN 444143-26-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STN Note 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 405046.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:20:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 115 TO ITERATE

100.0% PROCESSED 115 ITERATIONS
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1657 TO 2943

PROJECTED ANSWERS: 575 TO 1423

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 09:20:27 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2163 TO ITERATE

100.0% PROCESSED 2163 ITERATIONS

1039 ANSWERS

SEARCH TIME: 00.00.01

L3 1039 SEA SSS FUL L1

=> fil .search

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

140.28

140.49

FILE 'MEDLINE' ENTERED AT 09:20:35 ON 19 AUG 2002

FILE 'CAPLUS' ENTERED AT 09:20:35 ON 19 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:20:35 ON 19 AUG 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPATFULL' ENTERED AT 09:20:35 ON 19 AUG 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:20:35 ON 19 AUG 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> s l3 and peptid?

4 FILES SEARCHED...

L4 301 L3 AND PEPTID?

=> s l4 and link?

L5 153 L4 AND LINK?

=> s l5 and .imag?

L6 127 L5 AND .IMAG?

<-----User Break----->

=> s l5 and (mri or magnetic? or nuclear? or imag?)

L7 128 L5 AND (MRI OR MAGNETIC? OR NUCLEAR? OR IMAG?)

=> s l7 and (proteas? or interleukin? or cathespsin? or calpain?)

L8 42 L7 AND (PROTEAS? OR INTERLEUKIN? OR CATHESPSIN? OR CALPAIN?)

=> dup rem l8

PROCESSING COMPLETED FOR L8

L9 42 DUP REM L8 (0 DUPLICATES REMOVED)

=> d ibib ab hitstr 1-

YOU HAVE REQUESTED DATA FROM 42 ANSWERS - CONTINUE? Y/(N):y

L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:51305 CAPLUS
 DOCUMENT NUMBER: 136:123597
 TITLE: Preparation of stable radiopharmaceutical compositions
 useful for tumor therapy
 INVENTOR(S): Liu, Shuang; Barrett, John A.; Carpenter, Alan P., Jr.
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004030	A2	20020117	WO 2001-US21261	20010705


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: MARPAT 136:123597 US 2000-216396P P 20000706

OTHER SOURCE(S):
 AB The present invention provides stable radiopharmaceutical compns. including a therapeutic radionuclide and an effective stabilizing amt. of an arom. stabilizer (e.g., a polyhydroxylated arom. compd., an arom. amine, or a hydroxylated arom. amine), alone or in combination with other antioxidants or stabilizers, to inhibit radiolytic degradn. of radiopharmaceuticals. The present invention also provides improved radiopharmaceutical formulations by the use of an arom. stabilizing agent (e.g., a polyhydroxylated arom. compd., an arom. amine, or a hydroxylated arom. amine), and/or low temp. storage. The present invention also provides processes for making stable radiopharmaceutical compns. The present invention also provides the use of the pharmaceutical compns. in medical therapy and/or medical diagnosis.

IT 137076-54-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of chelator-optional linker-biomol. conjugates for use in stable radiopharmaceutical compns.)
 RN 137076-54-1 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetracetic acid, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)




IT 250612-82-9P 277316-41-3P 277316-45-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of chelator-optional linker-biomol. conjugates for use in stable radiopharmaceutical compns.)
 RN 250612-82-9 CAPLUS
 CN Cyclo(L-arginylglycyl-L- α -aspartyl-D-phenylalanyl-L-lysyl), 5,5'-[N-[[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoyl]bis-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 250612-81-8
 CMF C87 H137 N23 O23

L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 2-A



RN 277316-41-3 CAPLUS
 CN L-Alaninamide, 3-sulfo-N-[[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-alanyl-N-[2-[[[4-(4-[[[1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoyl]bis-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277316-45-7 CAPLUS
 CN L-Alaninamide,
 N-[[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoylbis[3-sulfo-L-alanyl-N-[2-[[[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-1-methyl-4-oxo-7-[[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]methyl]-3-(quinolinyl)carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




PAGE 1-D





L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A



PAGE 2-D



IT 250612-07-8P 277315-68-1P 277315-72-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (prepn. of chelator-optional linker-biomol. conjugates for
 use in stable radiopharmaceutical compns.)


RN 250612-07-8 CAPLUS
 CN Cyclo(L-arginylglycyl-L-.alpha.-aspartyl-D-phenylalanyl-L-lysyl),
 5,5'-[N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoyl]bis-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 250612-06-7
 CMF C75 H113 N23 O23

L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B




CM 2

CRN 76-05-1

L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C

CO₂H

CM 2

CRN 76-05-1

CMP C2 H F3 O2



RN 277315-72-7 CAPLUS

CN L-Alaninamide,

N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-

1-yl]acetyl]-L-glutamoylbis[3-sulfo-L-alanyl-N-[2-[[[4-[[[1S]-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CMP C2 H F3 O2



RN 277315-68-1 CAPLUS

CN L-Alaninamide, 3-sulfo-N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-alanyl-N-[2-[[[4-[[[1S]-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277315-67-0

CMP C54 H76 N14 O23 S3


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




PAGE 1-D




L9 ANSWER 2 OF 42 USPATFULL (Continued)

Complex.
 IT 114873-37-9, 1,4,7-Tri(carboxymethyl)-1,4,7,10-tetraazacyclododecane
 (conjugates of metal complexes and oligoribonucleotides which bind specifically to selected target structures)
 RN 114873-37-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (9CI) (CA INDEX NAME)



IT 146270-94-2P 174700-60-8P 174700-61-9P
 174700-62-0P 174700-63-1P 174701-09-8P
 (conjugates of metal complexes and oligoribonucleotides which bind specifically to selected target structures)
 RN 146270-94-2 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[3-amino-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 174700-60-8 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[3-[(2-carboxybenzoyl)amino]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


L9 ANSWER 2 OF 42 USPATFULL

ACCESSION NUMBER: 2002:149150 USPATFULL
 TITLE: CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION
 INVENTOR(S): DINKELBORG, LUDGER, BERLIN, GERMANY, FEDERAL REPUBLIC OF
 OF HILGER, CHRISTOPH-STEPHAN, BERLIN, GERMANY, FEDERAL REPUBLIC OF
 OF NIEDBALLA, ULRICH, BERLIN, GERMANY, FEDERAL REPUBLIC OF
 OF PLATZEK, JOHANNES, BERLIN, GERMANY, FEDERAL REPUBLIC OF
 OF RADUECHEL, BERND, BERLIN, GERMANY, FEDERAL REPUBLIC OF
 OF SPECK, ULRICH, BERLIN, GERMANY, FEDERAL REPUBLIC OF
 OF GOLD, LARRY, BOULDER, CO, UNITED STATES
 OF PIEKEN, WOLFGANG, LONGMONT, GERMANY, FEDERAL REPUBLIC OF

NUMBER	KIND	DATE
US 2002077306	A1	20020620
US 1995-488290	A1	19950607 (8)
Continuation-in-part of Ser. No. US 1994-358065, filed on 15 Dec 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-336127, filed on 4 Nov 1994, ABANDONED Continuation of Ser. No. US 1995-409813, filed on 24 Mar 1995, ABANDONED Continuation-in-part of Ser. No. 1994-357573, filed on 15 Dec 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-336128, filed on 4 Nov 1994, ABANDONED		


NUMBER	DATE
DE 1994-4424922	19940714
DE 1994-4445078	19941205
UTILITY APPLICATION	
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201	
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Page(s)
LINE COUNT:	2915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB This invention relates to chemically modified oligo-nucleotide conjugates that contain a complexing agent or complex that is bound by a connecting component to the oligonucleotides. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases.	
The oligonucleotide radical can bond specifically and with high bonding affinity to target structures and can thus produce a specific therapeutic or diagnostic effect by the bound complexing agent or	

L9 ANSWER 2 OF 42 USPATFULL (Continued)




RN 174700-61-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[3-[(4-carboxy-3-(4-nitrophenyl)-1-oxobutyl)amino]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 2 OF 42 USPATFULL (Continued)


PAGE 2-A



RN 174700-62-0 USPATFULL


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[3-[(4-aminophenyl)-4-carboxy-1-oxobutyl]amino]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L9 ANSWER 2 OF 42 USPATFULL (Continued)

PAGE 2-A




RN 174701-09-8 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-hydroxy-3-[(1-imino-4-mercaptobutyl)amino]propyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 2 OF 42 USPATFULL (Continued)


PAGE 2-A



RN 174700-63-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[3-[(4-carboxy-3-(4-isothiocyanatophenyl)-1-oxobutyl]amino]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L9 ANSWER 3 OF 42 USPATFULL

ACCESSION NUMBER: 2002:60677 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Reno, John M., Brier, WA, UNITED STATES
 Theodore, Louis J., Lynnwood, WA, UNITED STATES
 Gustavson, Linda M., Seattle, WA, UNITED STATES

NUMBER	KIND	DATE
US 2002034511	A1	20020321
US 2001-920454	A1	20010801 (9)

PATENT INFORMATION: US 2002034511 A1 20020321
 APPLICATION INFO.: US 2001-920454 A1 20010801 (9)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-788339, filed on 27 Jan 1997, GRANTED, Pat. No. US 6287536 Division of Ser. No. US 1993-122979, filed on 16 Sep 1993, GRANTED, Pat. No. US 5630996 Continuation of Ser. No. WO 1993-US5406, filed on 7 Jun 1993, UNKNOWN Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, UNKNOWN

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 15
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 17 Drawing Page(s)
 LINE COUNT: 4768


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

IT 60239-18-IDP, DOTA, biotin conjugates
 (prepn. of. for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 4 OF 42 USPATFULL
 ACCESSION NUMBER: 2002:60642 USPATFULL
 TITLE: Bioactivated diagnostic imaging contrast agents
 INVENTOR(S): Lauffer, Randall B., Brookline, MA, UNITED STATES
 McMurry, Thomas J., Winchester, MA, UNITED STATES
 Dunham, Stephen O., Madison, NJ, UNITED STATES
 Scott, Daniel M., Acton, MA, UNITED STATES
 Parmelee, David J., Belmont, MA, UNITED STATES
 Dumas, Stephane, Cambridge, MA, UNITED STATES
 PATENT ASSIGNEE(S): EPIX Medical, Inc. (U.S. corporation)

NUMBER	KIND	DATE
US 2002034476	A1	20020321
US 2001-952971	A1	20010914 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-823643, filed on 25 Mar 1997, PENDING

NUMBER	DATE
US 1996-14448P	19960401 (60)

PRIORITY INFORMATION: US 1996-14448P 19960401 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105
 NUMBER OF CLAIMS: 66
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1671

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.

IT 60239-18-1, DOTA 120041-08-9, HP-DO3A
 (contrast agent moiety: bioactivated diagnostic imaging contrast agents and prepn. thereof)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L9 ANSWER 5 OF 42 USPATFULL
 ACCESSION NUMBER: 2002:26860 USPATFULL
 TITLE: THREE-STEP PRETARGETING METHODS AND COMPOUNDS
 INVENTOR(S): THEODORE, LOUIS J., LYNNWOOD, WA, UNITED STATES
 RENO, JOHN M., BRIER, WA, UNITED STATES
 GUSTAVSON, LINDA M., SEATTLE, WA, UNITED STATES

NUMBER	KIND	DATE
US 2002015705	A1	20020207
US 6358490	B2	20020319
US 1999-316452	A1	19990521 (9)


RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-753445, filed on 25 Nov 1996, ABANDONED Division of Ser. No. US 1993-156614, filed on 23 Nov 1993, GRANTED, Pat. No.

US 5578287 Continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993, UNKNOWN
 Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, GRANTED, Pat. No. US 5283342


DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Page(s)
 LINE COUNT: 2235


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.
 IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 4 OF 42 USPATFULL (Continued)



RN 120041-08-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 42 USPATFULL
 ACCESSION NUMBER: 2002:8035 USPATFULL
 TITLE: Macrocylic chelants for metallopharmaceuticals
 INVENTOR(S): Liu, Shuang, Chelmsford, MA, UNITED STATES


NUMBER	KIND	DATE
US 2002004032	A1	20020110
US 2001-826549	A1	20010405 (9)

PRIORITY INFORMATION: US 2000-195234P 20000407 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Dupont Pharmaceuticals Company, Legal Department - Patents, 1007 Market Street, Wilmington, DE, 19898

NUMBER OF CLAIMS: 39
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to new macrocylic chelants and metal chelates thereof, methods of preparing the chelants and metal chelates, and pharmaceutical compositions comprising the macrocylic chelants and metal chelates. This invention relates particularly to the use of the new metal chelates as contrast agents in X-ray or CT, MRI imaging, and radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious disease and cancer. This invention also relates to new bifunctional chelants (BFCs) for attaching diagnostic metals and therapeutic isotopes to target-specific biomolecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands. In addition, the macrocylic chelants are useful for heavy metal detoxification.

IT 366792-24-7P
 (prepn. and complexation with rare earth metals)
 RN 366792-24-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[[1-(2-ethoxy-2-oxoethyl)-1,2-dihydro-3-hydroxy-2-oxo-4-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




L9 ANSWER 6 OF 42 USPATFULL (Continued)

IT 366792-26-9P

(prepn. and complexation with rare earth metals and indium)

RN 366792-26-9 USPATFULL


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]- (9CI) (CA INDEX NAME)



IT 366792-30-5

(reactant for prepn. of
(ethoxycarbonylmethylhydroxypyridinylmethyl
tetraazacyclododecanetriacetic acid)

RN 366792-30-5 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, tributyl ester (9CI)
(CA INDEX NAME)

L9 ANSWER 8 OF 42 USPATFULL

ACCESSION NUMBER: 2002:136533 USPATFULL

TITLE: Method for delivering bioactive agents using

cochleates

INVENTOR(S): Unger, Evan C., Tucson, AZ, United States

PATENT ASSIGNEE(S): Imarx Therapeutics, Inc., Tucson, AZ, United States
(U.S. corporation)

NUMBER	KIND	DATE
US 6403056	B1	20020611
US 2000-540448		20000331 (9)
Division of Ser. No. US 1997-925353, filed on 8 Sep 1997, now patented, Pat. No. US 6120751		
Continuation-in-part of Ser. No. US 1997-823791, filed on 21 Mar 1997, now patented, Pat. No. US 6143276		
Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997, now patented, Pat. No. US 6090800		
Continuation-in-part of Ser. No. US 1997-877826, filed on 18 Jun 1997, now patented, Pat. No. US 6143276		
Continuation-in-part of Ser. No. US 1997-887215, filed on 2 Jul 1997, now patented, Pat. No. US 6028066		
DOCUMENT TYPE: Utility		
FILE SEGMENT: GRANTED		
PRIMARY EXAMINER: Hartley, Michael G.		
LEGAL REPRESENTATIVE: Woodcock Washburn LLP		
NUMBER OF CLAIMS: 63		
EXEMPLARY CLAIM: 1		
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT: 6445		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention is directed to charged lipids, compositions comprising charged lipids, and the use of these compositions in drug delivery, targeted drug delivery, therapeutic imaging and diagnostic imaging, as well as their use as contrast agents.

IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid

(charged lipids for drug delivery, imaging, and as contrast agents)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 7 OF 42 USPATFULL

ACCESSION NUMBER: 2002:167864 USPATFULL

TITLE: Pretargeting methods and compounds

INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States

Axworthy, Donald B., Brier, WA, United States

Reno, John M., Brier, WA, United States

NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6416738	B1	20020709
US 2000-561736		20000425 (9)
Continuation of Ser. No. US 1994-350551, filed on 7 Dec 1994, now patented, Pat. No. US 6075010		
Continuation-in-part of Ser. No. US 1973-163184, filed on 7 Dec 1973, now abandoned		
Continuation-in-part of Ser. No. US 1993-055406, filed on 7 Jun 1993		
Continuation-in-part of Ser. No. US 1992-095381, filed on 23 Dec 1992, now abandoned		
Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		

1994, now patented, Pat. No. US 6075010
Continuation-in-part of Ser. No. US 1973-163184, filed on 7 Dec 1973, now abandoned
Continuation-in-part of Ser. No. US 1993-055406, filed on 7 Jun 1993
Continuation-in-part of Ser. No. US 1992-095381, filed on 23 Dec 1992, now abandoned
Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE:

FILE SEGMENT:

PRIMARY EXAMINER:

LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 29 Drawing Figure(s); 20 Drawing Page(s)

LINE COUNT: 5294

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Clearing agents and clearance mechanisms are also discussed.

IT 60239-18-1DP, DOA, biotin conjugates

(prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 9 OF 42 USPATFULL

ACCESSION NUMBER: 2002:57375 USPATFULL

TITLE: Somatostatin analogs

INVENTOR(S): Lister-James, John, Bedford, NH, United States

Dean, Richard T., Bedford, NH, United States

Pearson, Daniel A., Bedford, NH, United States

Wilson, David M., Bow, NH, United States

Berlex Laboratories, Inc., Montville, NJ, United States

PATENT ASSIGNEE(S): States
(U.S. corporation)

NUMBER	KIND	DATE
US 6358491	B1	20020319
US 1999-397792		19990916 (9)

NUMBER	DATE
US 1999-151001P	19990827 (60)

PRIORITY INFORMATION:

DOCUMENT TYPE:

FILE SEGMENT:

PRIMARY EXAMINER: Jones, Dameron L.

LEGAL REPRESENTATIVE: Tatsuya Ikeda, McDaniels, Patricia, Millen, White,

Zelano, and Branigan, P.C.

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel peptide-based pharmacophores and compounds which bind somatostatin receptors with high affinity and which exhibit improved pharmacokinetic properties over known somatostatin analogs. The pharmacophores and compounds of the invention may be used in labeled or unlabeled form for diagnosing and/or treating

somatostatin responsive diseases. The invention also provides radiopharmaceuticals and kits comprising these compounds, as well as methods for diagnosing and/or treating somatostatin receptor mediated diseases.


IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 114873-37-9, 1,4,7,10-Tetraazacyclododecane-1,4,7-

triacetic acid

(prepn. of novel somatostatin analogs)

RN 60239-18-1 USPATFULL


CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



RN 114873-37-9 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (9CI) (CA INDEX NAME)

L9 ANSWER 9 OF 42 USPATFULL (Continued)



L9 ANSWER 10 OF 42 USPATFULL

ACCESSION NUMBER: 2002:34178 USPATFULL
 TITLE: Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
 INVENTOR(S): Pivnick-Worms, David, Ladue, MO, United States
 PATENT ASSIGNEE(S): Washington University School of Medicine, St. Louis, MO, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6348185	B1	20020219
US 1999-336093		19990618 (9)

NUMBER	DATE
US 1998-90087P	19980620 (60)

PRIORITY INFORMATION: US 1998-90087P 19980620 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Jones, Dameron L.
 LEGAL REPRESENTATIVE: Senniger, Powers, Leavitt & Roedel
 NUMBER OF CLAIMS: 21
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 2698


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

IT 60239-18-1D, DOTA, peptide conjugates, complexes (membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:935597 CAPLUS
 DOCUMENT NUMBER: 136:54028
 TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
 INVENTOR(S): Rajopadhye, Milind; Barrett, John A.; Carpenter, Alan P., Jr.; Cheesman, Edward H.; Harris, Thomas D.
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 449 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098294	A2	20011227	WO 2001-US19794	20010621

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPL. INFO.: MARPAT 136:54028
 OTHER SOURCE(S):
 AB Compd. (Q)d-Ln-(Ch)d' (Q is a residue having an indazole-type moiety, d = 1-10, d' = 1-100, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer. The present invention provides novel compds. useful for the treatment of rheumatoid arthritis. Thus, 2-[[[4-[[[3-(2-(2-[3-[[[6-[[[1-aza-2-(2-sulfo-phenyl)vinyl]amino] (3-pyridyl)] carbonylamino] propoxy] ethoxy] ethoxy] propyl] amino] sulfonyl] phenyl] sulfonyl] amino] 3-[[[1-(3-indazole-2-ylamino)propyl] (1H-indazol-5-yl)] carbonylamino] propanoic acid was prepd. (claimed compd.). Syntheses of radiopharmaceuticals, e.g., 99mTc(VnA) (tricine) (phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

IT 277328-77-5P 277329-54-1P 277329-55-2P
 277329-57-4P 277329-58-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of vitronectin receptor antagonist pharmaceuticals)

RN 277328-77-5 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-[16-[[[4'-[[[15]-1-carboxy-2-[[[1-(3-(1H-indazol-2-ylamino)propyl]-1H-indazol-5-yl)] carbonylamino] ethyl] amino] sulfonyl] [1,1'-biphenyl]-4-yl] sulfonylamino]-2-oxo-7,10,13-trioxo-3-azahexadec-1-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 277328-76-4

CMP C55 H77 N13 O17 S2


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



CM 2

CRN 76-05-1

CMP C2 H F3 O2



RN 277329-54-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[(1R)-2-[[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277328-95-7

CMP C50 H72 N14 O18 S2

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 277329-55-2 CAPLUS

CN L-Alaninamide,

N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoylbis(N-2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277328-96-8


CMP C89 H123 N25 O31 S4

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



CM 2


CRN 76-05-1

CMP C2 H F3 O2




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



PAGE 1-D



CM 2

CRN 76-05-1

CMP C2 H F3 O2



RN 277329-57-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[(1R)-2-[[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CM 1


CRN 277328-97-9

CMP C50 H66 N14 O18 S3

Absolute stereochemistry.




PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



IT 277328-76-4P 277328-82-2P 277328-83-3P
 277328-84-4P 277328-85-5P 277328-86-6P
 277328-87-7P 277328-88-8P 277328-89-9P
 277328-90-2P 277328-91-3P 277328-92-4P
 277328-93-5P 277328-95-7P 277328-96-8P
 277328-97-9P 277328-98-0P 277328-99-1P
 277329-00-7P 277329-01-8P 277329-02-9P
 277329-03-0P 277329-04-1P 277329-05-2P
 277329-06-3P 277329-08-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of vitronectin receptor antagonist pharmaceuticals)

RN 277328-76-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,

10-[16-[[[4'-[[[(1S)-

1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonylamino]ethylamino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonylamino]-2-oxo-7,10,13-trioxo-3-azahexadec-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CM 2

CRN 76-05-1

CMP C3 H F3 O2




RN 277329-58-5 CAPLUS

CN L-.alpha.-Glutamine, N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonylamino]ethylamino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutylamino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277328-82-2 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonylamino]ethylamino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277328-84-4 CAPLUS
 CN L-Alanine, N,N'-[[[16S]-15,19-dioxo-16-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-4,7,10,24,27,30-hexaoxa-

14,20-diazatritriacontane-1,33-diyl]bis(iminosulfonyl[1,1'-biphenyl]-4',4'-diylsulfonyl)]bis[3-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-B



RN 277328-83-3 CAPLUS
 CN L-Alanine, N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoylbis[6-aminohexanoyl-3-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonylamino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



PAGE 1-D




RN 277328-85-5 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-[(4S)-4-carboxy-21-
 [[4'-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-
 indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-
 yl]sulfonyl]amino]-2,7-dioxo-12,15,18-trioxa-3,8-diazaheneicos-1-yl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277328-86-6 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4R)-24-[4-
 [[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-
 yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-2,5,21-trioxo-
 4-(sulfomethyl)-10,13,16-trioxa-3,6,20-triazatetracos-1-yl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277328-87-7 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-24-[4-
 [[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-
 yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-2,5,21-trioxo-
 4-[[4-(phosphonooxy)phenyl]methyl]-10,13,16-trioxa-3,6,20-triazatetracos-1-
 yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B




PAGE 1-C



RN 277328-88-8 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-24-(4-

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277328-89-9 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-24-(4-
 [[[1S]-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-
 yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-4-[3-[[2-
 [(3,6-di-O-sulfo-beta-D-galactopyranosyl)oxy]ethyl]amino]-3-oxopropyl]-
 2,5,21-trioxo-10,13,16-trioxo-3,6,20-triazatetracos-1-yl]- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
 [[[1S]-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-
 yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-2,5,21-trioxo-
 4-[[4-(sulfoxy)phenyl]methyl]-10,13,16-trioxo-3,6,20-triazatetracos-1-yl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277328-90-2 CAPLUS
 CN .beta.-Cyclodextrin,
 6A-[[24-[4-[[[1S]-1-carboxy-2-[[[1-[3-(1H-imidazol-2-
 yl]amino]propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-
 dimethylphenoxy]-1,5,21-trioxo-4-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-
 tetraazacyclododec-1-yl]acetyl]amino]-10,13,16-trioxo-6,20-diazatetracos-1-
 yl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A




PAGE 3-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 277328-92-4 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-3,5-dimethylphenoxy]-2,5,21-trioxo-10,13,16-trioxo-3,6,20-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 3-B




PAGE 3-C




RN 277328-91-3 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-[[7S]-27-[4-[[[(1S)-1-carboxy-2-[[[1-[3-[(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-4,8,24-trioxo-7-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-13,16,19-trioxo-3,9,23-triazaheptacos-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 277328-93-5 CAPLUS
 CN L-Lysineamide, N6-[N,N-bis(phosphonomethyl)glycyl]-N-[18-[4-[[[(1S)-1-carboxy-2-[[[1-[3-[(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-15-oxo-4,7,10-trioxo-14-azaoctadec-1-yl]-N2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 277328-95-7 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[1R]-2-[[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-imidazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 277328-96-8 CAPLUS


CN L-Alaninamide,
N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl]acetyl]-L-glutamoyl]bis[N-[[2-[[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-imidazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



PAGE 1-D




RN 277328-97-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[1R]-2-[[2-[[4'-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-imidazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 277328-98-0 CAPLUS

CN L-.alpha.-Glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[(1S)-1-carboxy-2-[[[1-[3-(2-pyridinylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 277328-99-1 CAPLUS


CN D-.alpha.-Glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




RN 277329-00-7 CAPLUS


CN L-Glutamamide, N-[1-oxo-6-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]hexyl]-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N1,N5-bis[2-[[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



PAGE 2-A




RN 277329-01-8 CAPLUS
 CN L-.alpha.-Glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[1S]-1-carboxy-2-[[[1-[[3-[[1,4,5,6-tetrahydro-2-pyrimidinyl]amino]propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 277329-02-9 CAPLUS
 CN L-.alpha.-Glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[1S]-1-carboxy-2-[[[1-methyl-3-[[3-[[3,4,5,6-tetrahydro-2-pyridinyl]amino]propyl]-1H-indazol-6-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277329-03-0 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[[4-[[[1S]-1-carboxy-2-[[[1-[[2-[[3,4,5,6-tetrahydro-2-pyridinyl]amino]ethyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-B



RN 277329-04-1 CAPLUS
 CN L-α-glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-α-glutamyl-N-2-[[[4'-[[[1S]-1-carboxy-2-[[[1-[2-[[3,4,5,6-tetrahydro-2-pyridinyl]amino]ethyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



RN 277329-05-2 CAPLUS
 CN L-α-glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-α-glutamyl-N-2-[[[4'-[[[1S]-1-carboxy-2-[[[1-[3-[[1,4,5,6-tetrahydro-2-pyrimidinyl]amino]propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277329-06-3 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[4'-[[[1S]-1-carboxy-2-[[[3-[[1H-imidazol-2-ylamino]methyl]-1-methyl-1H-indazol-6-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B




RN 277329-08-5 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[[3-[[5-[[[(2S)-


2-carboxy-2-[[[2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-
1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-7-yl]oxy]propyl]amino]-2-
oxoethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 192635-89-5 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
tris(1,1-dimethylethyl) phenylmethyl ester (9CI) (CA INDEX NAME)



```

RN      277329-25-6      CAPLUS
CN      1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[16-[[[4'-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-
yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl-4-
yl]sulfonyl]amino]-2-oxo-7,10,13-trioxo-3-azahexadec-1-yl]-,
.alpha.,.alpha.,.alpha.,.alpha.-tris(1,1-dimethylethyl) ester,
pentakis(trifluoroacetate) (9CI) (CA INDEX NAME)

```

CM 1

CRN 277329-24-5
CMF C67 H101 N13 O17 S2

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B




PAGE 2-A



```

IT 122555-91-3
   RL: RCT (Reactant); RACT (Reactant or reagent)
      (prepn. of vitronectin receptor antagonist pharmaceuticals)
RN 122555-91-3 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, tris(1,1-
   dimethylethyl) ester (9CI) (CA INDEX NAME)


```




IT	137076-54-1P	192635-89-5P	277329-25-6P
	277329-52-9P	277329-70-1P	277327-77-8P
	277329-94-9P	277330-01-5P	277330-02-6P
	277330-07-1P	277330-12-6P	277330-13-9P
	277330-22-0P	277330-27-5P	277330-44-6P
	277330-49-1P		
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)		
	(prepn. of vitronectin receptor antagonist pharmaceuticals)		
RN	137076-54-1	CAPLUS	
CN	1,4,7,10-Tetra[1,1-dimethylododecanoate] 4,4',7,10-tetracarboxic acid, tri[1,1-dimethyl-2-ethylester] (9CI), [CA INDEX NAME]		

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



PAGE 2-C




CM 2

CRN 76-05-1
CMP C2 H F3 O2

RN 277329-52-9 CAPLUS
CN D-.alpha.-Glutamine, N-[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-(4-

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




RN 277329-70-1 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[1R]-2-[[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-L-.alpha.-.alpha.-.alpha.'-tris(1,1-dimethylethyl) ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277329-69-8
CMP C62 H96 N14 O18 S2

Absolute stereochemistry.


PAGE 1-A




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-, 1,25-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



CM 2

CRN 76-05-1
CMP C2 H F3 O2

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 277329-77-8 CAPLUS

CN L-Alaninamide,

N-[[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamylbis[N-[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277329-76-7

CMF C101 H147 N25 O31 S4


Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-D



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 277329-94-9 CAPLUS

1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[(1R)-2-[[[2-[[[4'-[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-, .alpha.,.alpha.,.alpha.''-tris(1,1-dimethylethyl) ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 277329-93-8

CMF C62 H90 N14 O18 S3


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B




PAGE 1-C




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



PAGE 2-B



L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
PAGE 2-C




CM 2

CRN 76-05-1
CMP C2 H P3 O2



RN 277330-01-5 CAPLUS
CN L-.alpha.-Glutamine, N-[[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[[(1S)-2-methoxy-2-oxo-1-[[[1-[3-(2-pyridinylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]methyl]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 277330-07-1 CAPLUS
CN L-.alpha.-Glutamine, N-[[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277330-02-6 CAPLUS
CN D-.alpha.-Glutamine, N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[[(1S)-1-carboxy-2-[[[1-[3-(2-pyridinylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-, 1,25-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
[[[[(1S)-1-carboxy-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-, 1,25-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




RN 277330-12-8 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) 2,3,5,6-tetrafluorophenyl ester (9CI) (CA INDEX NAME)



RN 277330-13-9 CAPLUS
 CN L-Glutamide, N-[1-oxo-6-[[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]hexyl]-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N1,N5-bis[2-[[4-(4-[[[(1S)-1-carboxy-2-[[[1-(3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]ethyl]amino)sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A



PAGE 2-B




RN 277330-22-0 CAPLUS
 CN .alpha.-Glutamine, N-[[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-(4-[[[(1S)-2-methoxy-2-oxo-1-[[[1-(3-(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]-1H-indazol-5-yl]carbonyl]amino]methyl]ethyl]amino)sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



RN 277330-27-5 CAPLUS
 CN L-.alpha.-Glutamine, N-[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[(1S)-2-methoxy-1-[[[1-methyl-3-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propyl]-1H-indazol-6-yl]carbonyl]amino]methyl]-2-oxoethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277330-44-6 CAPLUS
 CN L-.alpha.-Glutamine, N-[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4'-[[[(1S)-2-methoxy-2-oxo-1-[[[1-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propyl]-1H-indazol-5-yl]carbonyl]amino]methyl]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]ethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277330-49-1 CAPLUS
 CN .alpha.-Glutamine, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-glutamyl-N-[2-[[4-[[[(1S)-2-methoxy-2-oxo-1-[[[1-[[3-(2-pyridinylamino)propyl]-1H-indazol-5-yl]carbonyl]amino]methyl]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)




IT 122555-91-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of peptide derive. for the **imaging** of
angiogenic disorders and the treatment of cancer in combination
therapy)

RN 122555-91-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, tris(1,1-
dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 137076-54-1P 192635-89-5P 250612-82-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of peptide derive. for the **imaging** of
angiogenic disorders and the treatment of cancer in combination
therapy)

RN 137076-54-1 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 192635-89-5 CAPLUS

L9 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 2-A


CM 2

CRN 76-05-1
CMP C2 H F3 O2



L9 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
tris(1,1-dimethylethyl) phenylmethyl ester (9CI) (CA INDEX NAME)



RN 250612-82-9 CAPLUS


CN Cyclo(L-arginylglycyl-L- alpha -aspartyl-D-phenylalanyl-L-lysyl),
5,5'-[N-[[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-
tetraazacyclododec-1-yl]acetyl]-L-glutamyl]bis-, bis(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 250612-81-8

CMP C87 H137 N23 O23

PAGE 1-A



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:935440 CAPLUS

DOCUMENT NUMBER: 136:70082

TITLE: Vitronectin receptor antagonist pharmaceuticals for
use in combination therapy

INVENTOR(S): Harris, Thomas D.; Barrett, John A.; Carpenter, Alan
P., Jr.; Rajopadhye, Milind

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 542 pp.

DOCUMENT TYPE: CODEN: PIXXD2

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: 1 English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097848	A2	20011227	WO 2001-US19793	20010621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-213210P P 20000621

OTHER SOURCE(S): MARPAT 136:70082

AB Anticancer agents of the formulas (Q)d-Ln-Ch or (Q)d-Ln-(Ch)d (I) [Q is a
residue having a quinolone-type moiety; Ln is a linking group;
Ch is a metal-bonding unit; d = 1-10; d' = 1-100] and kits contg. I are
prepd. for the treatment of cancer in combination therapy in a patient.

I are comprised of a targeting moiety that binds to a receptor that is
upregulated during angiogenesis, an optional linking group, and
a therapeutically effective radioisotope or diagnostically effective
imaging moiety. I may be used with radioisotopes; in addn., I
may be used in conjunction with radio- and photosensitizers, ligands such
as TPPTS or tricine, and reducing agents such as tin(II). The present
invention provides novel compds. useful for the treatment of rheumatoid
arthritis (no data).

IT 277315-54-5P 277315-66-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of peptide- and tetraazadodecane-contg. quinolones
and their radioactive metal complexes as anticancer agents)

RN 277315-54-5 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[[16-[[[4'-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolonyl]carbonyl]amino]ethyl]amino]sulfonyl] [1,1'-biphenyl]-4-yl]sulfonyl]amino]-2-oxo-7,10,13-trioxo-3-azahexadec-1-yl]-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277315-53-4


CMP C56 H76 N12 O18 S2

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



CM 2

CRN 76-05-1

CMF C2 H P3 O2



RN 277315-66-9 CAPLUS

CN L-.alpha.-Asparagine, N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-aspartyl-N-[22-[3-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[[1H-imidazol-2-ylamino]methyl]-4-oxo-1(4H)-quinolinyl]-15,18-dioxo-4,7,10-trioxo-14,19-diazadocos-1-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277315-65-8

CMF C67 H97 N15 O24 S

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CM 2

CRN 76-05-1

CMF C2 H P3 O2



IT 277315-53-4P 277315-65-8P 277315-67-0P
277315-68-1P 277315-69-2P 277315-70-5P
277315-72-7P 277315-74-9P 277315-75-0P
277315-76-1P 277315-77-2P 277315-79-4P
277315-80-7P 277316-60-6P 277316-61-7P
277316-62-8P 277316-63-9P 277316-64-0P
277316-65-1P 277316-66-2P 277316-67-3P
277316-68-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide- and tetraazadodecane-contg. quinolones and their radioactive metal complexes as anticancer agents)


RN 277315-53-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[16-[[[4'-[[[(1S)-

1-carboxy-2-[[[(1,4-dihydro-7-[[[1H-imidazol-2-ylamino]methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]sulfonyl]amino]-2-oxo-7,10,13-trioxo-3-azahexadec-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



RN 277315-65-8 CAPLUS
 CN L-.alpha.-Asparagine, N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-.alpha.-aspartyl-N-[22-[3-[[[(2S)-2-carboxy-2-[[[2,4,6-trimethylphenyl]sulfonyl]amino]ethyl]amino]carbonyl]-7-[[[1H-imidazol-2-ylamino]methyl]-4-oxo-1(4H)-quinolinyl]-15,18-dioxo-4,7,10-

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C




RN 277315-67-0 CAPLUS
 CN L-Alaninamide, 3-sulfo-N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-alanyl-N-[2-[[[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[[[1H-imidazol-2-ylamino]methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




RN 277315-68-1 CAPLUS
 CN L-Alaninamide, 3-sulfo-N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-alanyl-N-[2-[[[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[[[1H-imidazol-2-ylamino]methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 277315-67-0
 CMF C54 H76 N14 O23 S3

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C

CO₂H

CM 2

CRN 76-05-1

CMP C2 H F3 O2



RN 277315-69-2 CAPLUS


CN L-Alaninamide,

N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-

1-yl]acetyl]-L-glutamoylbis[N-[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[[[1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-D



RN 277315-70-5 CAPLUS

CN L-Alaninamide,

N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-

1-yl]acetyl]-L-glutamoylbis[N-[2-[[4-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[[[1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277315-69-2

CMP C91 H121 N23 O33 S4


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B




PAGE 1-C




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-B



PAGE 1-C



PAGE 1-D



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CM 2


CRN 76-05-1
CMP C2 H F3 O2

RN 277315-72-7 CAPLUS
CN L-Alaninamide,
N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-

1-yl]acetyl]-L-glutamoylbis[3-sulfo-L-alanyl-N-[2-[[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[[1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-D




RN 277315-74-9 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[3-[[[(2S)-

2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[[[1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B




PAGE 1-C




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 277315-75-0 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[3-[[[(2S)-

2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[[[1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxoethyl)-, tria(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277315-74-9
CMP C45 H61 N11 O13 S


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A

RN 277315-77-2 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[[(1R)-2-[[3-[[3-


[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[[[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 277315-76-1
CMF C48 H66 N12 O17 S2

Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


RN 277315-76-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[[(1R)-2-[[3-[[3-

[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[[[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


CO2H

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B

CO2H

PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 277315-79-4 CAPLUS


CN L-Alaninamide,

N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl]acetyl]-L-glutamoylbis[N-[[3-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-7-[[[(1H-imidazol-2-ylamino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]-3-sulfo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A



RN 277315-80-7 CAPLUS
 CN L-Alaninamide,
 N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-
 1-yl]acetyl]-L-glutamoylbis[N-[3-{[[(2S)-2-carboxy-2-[[[2,4,6-
 trimethylphenyl]sulfonyl]amino]ethyl]amino]carbonyl]-7-[[1H-imidazol-2-
 yl]amino)methyl]-4-oxo-1(4H)-quinolinyl]propyl]-3-sulfo-,
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 277315-79-4

CMP C85 H111 N21 O29 S4

Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A



CM 2

CRN 76-05-1

CMP C2 H F3 O2




RN 277316-60-6 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[[4(5)-30-[3-
 [[[2S)-2-carboxy-2-[[[2,4,6-trimethylphenyl]sulfonyl]amino]ethyl]amino]ca
 rbonyl]-7-[[1H-imidazol-2-yl]amino)methyl]-4-oxo-1(4H)-quinolinyl]-4-[24-[3-
 [[[2S)-2-carboxy-2-[[[2,4,6-trimethylphenyl]sulfonyl]amino]ethyl]amino]ca
 rbonyl]-7-[[1H-imidazol-2-yl]amino)methyl]-4-oxo-1(4H)-quinolinyl]-1,17,20-
 trioxo-6,9,12-trioxa-2,16,21-triazatetracos-1-yl]-2,7,23,26-tetraoxo-
 12,15,18-trioxa-3,8,22,27-tetraazatriacont-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



PAGE 1-D



RN 277316-61-7 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-24-[4-[[[1S]-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-

dimethylphenoxy]-2,5,21-trioxo-4-[[[4-(phosphonoxy)phenyl]methyl]-10,13,16-trioxo-3,6,20-triazatetrasco-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




RN 277316-62-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4R)-24-[4-[[[1S]-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-2,5,21-trioxo-4-(sulfomethyl)-10,13,16-trioxo-3,6,20-triazatetrasco-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277316-63-9 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-24-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-4-[3-[[2-[(3,6-di-O-sulfo-.beta.-D-galactopyranosyl)oxy]ethyl]amino]-3-oxopropyl]-2,5,21-trioxo-4-[[4-(sulfooxy)phenyl]methyl]-10,13,16-trioxa-3,6,20-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277316-64-0 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-24-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-4-[3-[[2-[(3,6-di-O-sulfo-.beta.-D-galactopyranosyl)oxy]ethyl]amino]-3-oxopropyl]-2,5,21-trioxo-4-[[4-(sulfooxy)phenyl]methyl]-10,13,16-trioxa-3,6,20-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C




RN 277316-65-1 CAPLUS
 CN .beta.-Cyclodextrin,
 6A-[[24-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1,5,21-trioxo-4-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-10,13,16-trioxa-6,20-diazatetracos-1-yl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 2-A




PAGE 3-A




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 277316-67-3 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-4-(4-aminobutyl)-24-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-2,5,21-trioxo-10,13,16-trioxa-3,6,20-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 3-B




PAGE 3-C




RN 277316-66-2 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-[[[7S]-27-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-4,8,24-trioxo-7-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-13,16,19-trioxa-3,9,23-triazasheptacos-1-yl]-.omega.-methoxy- (9CI) (CA INDEX NAME)

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 277316-68-4 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[(4S)-4-[[[bis[(phosphonomethyl)amino]acetyl]amino]butyl]-24-[4-[[[(1S)-1-carboxy-2-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-


L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
2,5,21-trioxo-10,13,16-trioxo-3,6,20-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




IT 122555-91-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of peptide- and tetraazadodecane-contg. quinolones
and their radioactive metal complexes as anticancer agents)
RN 122555-91-3 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 137076-54-1P 192635-89-5P 277315-88-5P
277316-20-8P 277316-34-4P 277316-39-5P
277316-41-3P 277316-45-7P 277316-47-9P
277316-52-6P 277316-56-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of peptide- and tetraazadodecane-contg. quinolones
and their radioactive metal complexes as anticancer agents)
RN 137076-54-1 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
tris(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)



RN 192635-89-5 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
tris(1,1-dimethylethyl) phenylmethyl ester (9CI) (CA INDEX NAME)



RN 277315-88-5 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[16-[[[4'-[[[15]-
1-[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino)methyl]-1-methyl-4-oxo-3-
quinolinyl]carbonyl]amino]methyl]-2-methoxy-2-
oxoethyl]amino]sulfonyl] [1,1'-biphenyl]-4-yl]sulfonyl]amino]-2-oxo-7,10,13-
trioxo-3-azahexadec-1-yl]-, tris(1,1-dimethylethyl) ester,
pentakis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277315-87-4
CMF C69 H102 N12 O18 S2


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A




PAGE 1-B



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C



CM 2

CRN 76-05-1



CMP C2 H F3 O2



RN 277316-20-8 CAPLUS
 CN L- α -Asparagine, N-[[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L- α -aspartyl-N-[22-[3-[[[(2S)-3-methoxy-3-oxo-2-[[2,4,6-trimethylphenyl]sulfonyl]amino]propyl]amino]carbonyl]-4-oxo-7-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]methyl]-1(4H)-quinolinyl]-15,18-dioxo-4,7,10-trioxo-14,19-

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-C



RN 277316-34-4 CAPLUS
 CN L-Alaninamide,
 3-sulfo-N-[[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-alanyl-N-[2-[[[4-[[[(1S)-1-[[[1,4-dihydro-1-methyl-4-oxo-7-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]methyl]-3-quinolinyl]carbonyl]amino]methyl]-2-methoxy-2-oxoethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A


L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
 diazadocose-1-yl)-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



RN 277316-39-9 CAPLUS
 CN L-Alaninamide,
 N-[[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoylbis[N-[2-[[[4-[[[(1S)-1-[[[1,4-dihydro-1-methyl-4-oxo-7-[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]methyl]-3-quinolinyl]carbonyl]amino]methyl]-2-methoxy-2-oxoethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 277316-38-8

CMP C143 H177 N23 O33 S4


Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)



PAGE 1-A



PAGE 1-B



PAGE 1-D



CM 2
CRN 76-05-1
CMP C2 H F3 O2




RN 277316-41-3 CAPLUS

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


CN L-Alaninamide,
3-sulfo-N-[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-alanyl-N-[2-[[4-[[[1S]-1-carboxy-2-[[[1,4-dihydro-1-methyl-4-oxo-7-[[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]methyl]-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C




OBU-t

RN 277316-45-7 CAPLUS

CN L-Alaninamide,
N-[[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoylbis[3-sulfo-L-alanyl-N-[2-[[4-[[[1S]-1-carboxy-2-[[[1,4-dihydro-1-methyl-4-oxo-7-[[[1-(triphenylmethyl)-1H-imidazol-2-yl]amino]methyl]-3-quinolinyl]carbonyl]amino]ethyl]amino]sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 1-C



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

RN 277316-47-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[[3-[3-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]carbonyl]-
7-[[[1H-imidazol-2-ylamino]methyl]-4-oxo-1(4H)-quinolinyl]propyl]amino]-2-
oxoethyl]-, .alpha.,.alpha.,.alpha.''-tris(1,1-dimethylethyl) ester,
tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277316-46-8


CMP C57 H85 N11 O13 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-D



PAGE 2-A



PAGE 2-D



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

CRN 76-05-1

CMP C2 H F3 O2



RN 277316-52-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
10-[2-[[[1R]-2-[[[3-[3-[[[(2S)-2-carboxy-2-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]ethyl]amino]ca
rbonyl]-7-[[[1H-imidazol-2-ylamino]methyl]-4-oxo-1(4H)-
quinolinyl]propyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]-,
.alpha.,.alpha.,.alpha.''-tris(1,1-dimethylethyl) ester,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277316-51-5

CMP C60 H90 N12 O17 S2


Absolute stereochemistry.

PAGE 1-A



L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 277316-56-0 CAPLUS
CN L-Alaninamide,
N-[[4,7,10-tris(2-(1,1-dimethylethoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-glutamoylbis[N-(3-[[[(2S)-2-carboxy-2-
[[2,4,6-trimethylphenyl]sulfonyl]amino]ethyl]amino]carbonyl]-7-[[1H-
imidazol-2-ylamino]methyl]-4-oxo-1(4H)-quinolinyl]propyl]-3-sulfo-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 277316-55-9
CMF C97 H135 N21 O29 S4

Absolute stereochemistry.

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 2-A




CM 2


CRN 76-05-1
CMF C2 H F3 O2

L9 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:617999 CAPLUS
DOCUMENT NUMBER: 135:180952
TITLE: Preparation of matrix metalloproteinase inhibitors
INVENTOR(S): Decicco, Carl P.; Nelson, David J.; Barrett, John A.;
Carpenter, Alan P., Jr.; Duran, James J.; Rajopadhye,
Milind
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060820	A2	20010823	WO 2001-US4848	20010215
WO 2001060820	A3	20020221		

W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ,
PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR

PRIORITY APPLN. INFO.: US 2000-182627P P 20000215
OTHER SOURCE(S): MARPAT 135:180952

AB Comps. Qd-Ln-Ch (Qd is 1-10 targeting moieties; Ln is a linking group; Ch is a chelator) were prepd. The chelator is able to conjugate a cytotoxic radioisotope. The targeting moiety, e.g., R1NHCOCR2R3NR4R5 [R1 = OH or Ph, which is optionally substituted with a bond to the linking group or to the chelator, provided when R1 = Ph, R3 = 2-[(1-carboxyethyl)amino]alkanoyl; R2, R3, R4, R5 = H, C1-6, which is alkyl optionally substituted with a bond to the linking group or to the chelator; R2R3C or R4R5N may form a ring], is a matrix metalloproteinase inhibitor. Thus, peptidomimetic I was prepd. by coupling reactions of (3-aminopropyl)carbamate acid tert-Bu ester with oxazabicyclo[10.2.2]hexadecatrienecarboxylic acid derivs. Comps. of

the invention were found to be active in matrix metalloproteinase inhibitory assays.

IT 355149-94-9P 355149-95-OP 355149-96-1P
355149-97-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of matrix metalloproteinase inhibitors)

RN 355149-94-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[[2-[[3-


[[[[[(6S,7R,10S)-6-[(hydroxyamino)carbonyl]-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-12,14,15-trien-10-yl]carbonyl]amino]acetyl]amino]propyl]amino]-2-oxoethyl]- (9CI) (CA

INDEX
NAME)

Absolute stereochemistry.

L9 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


PAGE 1-A



PAGE 1-B

L9 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Bu-i



RN 355149-95-0 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[4-

[[[(6S,7R,10S)-6-[(hydroxyamino)carbonyl]-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-12,14,15-trien-10-yl]carbonyl]amino]methyl]phenyl]methyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Bu-i




RN 355149-96-1 CAPLUS

L9 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[[[4R)-14-[[[(6S,7R,10S)-6-[(hydroxyamino)carbonyl]-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-12,14,15-trien-10-yl]-2,5,11,14-tetraoxo-4-(sulfomethyl)-3,6,10,13-tetraazatetradec-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 355149-97-2 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[[(1R)-2-[[[4-

[[[(6S,7R,10S)-6-[(hydroxyamino)carbonyl]-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-12,14,15-trien-10-yl]carbonyl]amino]methyl]phenyl]methyl]amino]-2-oxo-1-(sulfomethyl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A



PAGE 1-B



L9 ANSWER 15 OF 42 USPATFULL
 ACCESSION NUMBER: 2001:196588 USPATFULL
 TITLE: Dense star polymer conjugates as dyes
 INVENTOR(S): Tomella, Donald A., Midland, MI, United States
 Kaplan, Donald A., Cincinnati, OH, United States
 Kruper, Jr., William J., Sanford, MI, United States
 Cheng, Roberta C., Midland, MI, United States
 Tomlinson, Ian A., Midland, MI, United States
 Fazio, Michael J., Midland, MI, United States
 Hedstrand, David M., Midland, MI, United States
 Wilson, Larry R., Beaverton, MI, United States
 The Dow Chemical Company, Midland, MI, United States
 (U.S. corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE

 PATENT INFORMATION: US 6312679 B1 20011106
 APPLICATION INFO.: US 1993-36644 19930324 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-654851, filed
 on 13 Feb 1991, now patented, Pat. No. US 5338532
 Continuation-in-part of Ser. No. US 1989-386049, filed
 on 26 Jul 1989, now abandoned Continuation-in-part of
 Ser. No. US 1987-87266, filed on 18 Aug 1987, now
 abandoned Continuation-in-part of Ser. No. US
 1986-897455, filed on 18 Aug 1986, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Levy, Neil S.
 LEGAL REPRESENTATIVE: Kimble, Karen L.
 NUMBER OF CLAIMS: 70
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
 LINE COUNT: 2900
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Starburst conjugates which are composed of at least one dendrimer in
 association with at least one unit of a carried agricultural,
 pharmaceutical, or other material have been prepared. These conjugates
 have particularly advantageous properties due to the unique
 characteristics of the dendrimer.


IT 371976-90-8P
 (dense star polymer conjugates as dyes)
 RN 371976-90-8 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-(2-hydroxyethyl)-,
 trimethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 16 OF 42 USPATFULL
 ACCESSION NUMBER: 2001:152454 USPATFULL
 TITLE: Two-step pretargeting methods using improved
 biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S.
 corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE


 PATENT INFORMATION: US 6287536 B1 20010911
 APPLICATION INFO.: US 1997-788339 19970127 (8)
 RELATED APPLN. INFO.: Division of Ser. No. US 1993-122979, filed on 16 Sep
 1993, now patented, Pat. No. US 5630996 Continuation
 of Ser. No. WO 1993-US5406, filed on 7 Jun 1993, now
 abandoned Continuation-in-part of Ser. No. US
 1992-995381, filed on 23 Dec 1992, now abandoned
 Continuation-in-part of Ser. No. US 1992-895588, filed
 on 9 Jun 1992, now patented, Pat. No. US 5283342
 DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Saunders, David
 LEGAL REPRESENTATIVE: SEED Intellectual Property Law Group PLLC
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 17 Drawing Page(s)
 LINE COUNT: 4802
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted
 delivery of diagnostic and therapeutic agents are disclosed. In
 particular, methods for radiometal labeling of biotin and for improved
 radiohalogenation of biotin, as well as related compounds, are
 described. Also, clearing agents, anti-ligand-targeting moiety
 conjugates, target cell retention enhancing moieties and additional
 methods are disclosed.


IT 60239-18-1DP, DOTA, biotin conjugates
 (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX
 NAME)



L9 ANSWER 15 OF 42 USPATFULL (Continued)



IT 60239-18-1P, DOTA
 (thiourea-linked; dense star polymer conjugates as dyes)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX
 NAME)




L9 ANSWER 17 OF 42 USPATFULL
 ACCESSION NUMBER: 2001:71530 USPATFULL
 TITLE: Cell-specific contrast agent and gene delivery
 vehicles
 INVENTOR(S): Kayyem, Jon Faiz, 428 S. Sierra Bonita, Pasadena, CA,
 United States 91106
 Meade, Thomas J., 1656 New York Dr., Altadena, CA,
 United States 91001
 Fraser, Scott E., 720 Bison Ave., Newport Beach, CA,
 United States 92660

NUMBER KIND DATE

 PATENT INFORMATION: US 6232295 B1 20010515
 APPLICATION INFO.: US 1994-321552 19941012 (8)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Priebe, Scott D.
 LEGAL REPRESENTATIVE: Trecartin, Richard F. Flehr Hohbach Test Albritton &
 Herbert LLP, Silva, Robin M.
 NUMBER OF CLAIMS: 2
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
 LINE COUNT: 761
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A delivery vehicle is described that is capable of being specifically
 bound to and taken into targeted cells, delivering numerous
 paramagnetic ions for magnetic resonance imaging (MRI)
 of the cells. The delivery vehicle comprises a polymeric molecule
 having a net positive charge complexed with another polymeric molecule having
 a net negative charge. Cell targeting moieties and MRI contrast
 agents are attached to one or both of the polymeric molecules. In one
 embodiment, the polymeric molecule having a net negative charge is a
 nucleic acid. Thus, the delivery vehicles can be used in clinical
 protocols in which nucleic acids for gene therapy and agents for
 MRI contrast are co-transported to specific cells allowing
 medical imaging monitoring of nucleic acid delivery.

IT 60239-18-1, DOTA
 (cell-specific gene delivery vehicles for delivery of paramagnetic
 ions)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX
 NAME)



L9 ANSWER 18 OF 42 USPATFULL
 ACCESSION NUMBER: 2001:55447 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Meyer, Damon L., Bellevue, WA, United States
 Mallett, Robert W., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)


NUMBER	KIND	DATE
US 6217869	B1	20010417
US 1997-926336		19970905 (8)

RELATED APPL. INFO.: Continuation of Ser. No. US 1994-351005, filed on 7 Dec
 1994, now abandoned Continuation-in-part of Ser. No.


US 163188, now abandoned Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Saunders, David
 LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 6397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed.
 IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 19 OF 42 USPATFULL (Continued)



L9 ANSWER 19 OF 42 USPATFULL
 ACCESSION NUMBER: 2001:13940 USPATFULL
 TITLE: Method to enhance tissue accumulation of radiolabeled compounds
 INVENTOR(S): Woltering, Eugene A., Kenner, LA, United States
 Espenan, Gregory D., Metairie, LA, United States
 PATENT ASSIGNEE(S): Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6180082	B1	20010130
US 1998-198562		19981123 (9)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Jones, Damron
 LEGAL REPRESENTATIVE: Davis, Bonnie J., Runnels, John H.
 NUMBER OF CLAIMS: 57
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 28 Drawing Figure(s); 28 Drawing Page(s)
 LINE COUNT: 2008


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that accumulates in the target cell. The efficacy of the administration of the radiolabeled compound can be increased about five times higher than prior bolus injection or short infusion methods. This method enhances the tumor to background ratio by increasing the actual radioligand accumulated inside the target cells. This technique works for any radiolabeled compound whose cellular uptake is limited by a cellular process of either binding to a cellular receptor or to a transport protein. Once the radiolabeled compound is bound and internalized, the ability of an unlabeled compound to compete with the radioligand is markedly decreased. The primary factor governing residence time after internalization is the physical half-life of the radioisotope, not biologic half-life.
 IT 60239-18-1D, DOTA, radiolabeled somatostatin conjugates (method for enhancing tumor and angiogenic tissue accumulation of radiopharmaceuticals)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L9 ANSWER 20 OF 42 USPATFULL
 ACCESSION NUMBER: 2000:91955 USPATFULL
 TITLE: Lipid soluble steroid prodrugs
 INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
 Shen, DeKang, Tucson, AZ, United States
 PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 6090800		20000718
US 1997-851780		19970506 (8)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Dees, Jose' G.
 ASSISTANT EXAMINER: Badio, Barbara
 LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 LINE COUNT: 6285


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is directed to novel lipid soluble steroid prodrugs comprising steroid prodrugs, and uses of the same.
 IT 60239-18-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (charged lipids for drug delivery, imaging, and as contrast agents)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 21 OF 42 USPATFULL
 ACCESSION NUMBER: 2000:7398 USPATFULL
 TITLE: Biotinamido-n-methylglycyl-ε-eryl-o-succinamido-benzyl
 dota
 INVENTOR(S): Theodore, Louis J., Lynnwood, WA, United States
 Kasina, Sudhakar, Kirkland, WA, United States
 Reno, John M., Brier, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S.
 corporation)

L9 ANSWER 21 OF 42 USPATFULL (Continued)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015897		20000118
APPLICATION INFO.:	US 1996-645211		19960513 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-351005, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Christina Y.		
ASSISTANT EXAMINER:	Gambel, Phillip		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	6303		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. Biotinamido-N-methylglycyl-ε-eryl-O-succinamido-benzyl DOTA is disclosed.		
IT	60239-18-1DDP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)		
RN	60239-18-1 USPATFULL		
CN	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)		



L9 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:819407 CAPLUS
 DOCUMENT NUMBER: 132:61087
 TITLE: Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
 INVENTOR(S): Pivnicka-Worms, David
 PATENT ASSIGNEE(S): Washington University, USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967284	A2	19991229	WO 1999-US13660	19990618
WO 9967284	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GE, GD, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2328457	A1	19991229	CA 1999-2328457	19990618
AU 9946905	A1	20000110	AU 1999-46905	19990618
EP 1090032	A2	20010411	EP 1999-930351	19990618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6348185	B1	20020219	US 1999-336093	19990618
JP 2002518521	T2	20020625	JP 2000-555935	19990618
PRIORITY APPLN. INFO.: US 1998-900877 P 19980620 WO 1999-US13660 W 19990618				


AB Methods and compns. for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

IT 60239-18-ID, DOTA, peptide conjugates, complexes
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy)

RN 60239-18-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L9 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2002 ACS (Continued)




L9 ANSWER 23 OF 42 USPATFULL
 ACCESSION NUMBER: 1999:141269 USPATFULL
 TITLE: Magnetic resonance imaging agents
 for the detection of physiological agents
 INVENTOR(S): Meade, Thomas, Altadena, CA, United States
 Fraser, Scott, La Canada, CA, United States
 Jacobs, Russell, Arcadia, CA, United States
 Li, Wenhong, Pasadena, CA, United States
 PATENT ASSIGNEE(S): Research Corporation Technologies, Tucson, AZ, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5980862		19991109
US 1998-134072		19980813 (9)
Continuation of Ser. No. US 1995-460511, filed on 2 Jun 1995, now abandoned Ser. No. US 1995-486968, filed on 7 Jun 1995, now patented, Pat. No. US 5707605 And Ser. No. US 971855		

NUMBER	DATE
US 1997-63328P	19971027 (60)


PRIORITY INFORMATION:
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Clardy, S. Mark
 ASSISTANT EXAMINER: Jones, Dameron
 LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert, Trecartin, Esq., Richard F., Silva, Esq., Robin M.

NUMBER OF CLAIMS: 1
 EXEMPLARY CLAIM: 33
 NUMBER OF DRAWINGS: 26 Drawing Figure(s); 15 Drawing Page(s)
 LINE COUNT: 2068
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.
 IT 60239-18-1, DOTA
 (chelator for prepn. of MRI contrast agents)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




IT 185948-90-7P

L9 ANSWER 23 OF 42 USPATFULL (Continued)



L9 ANSWER 23 OF 42 USPATFULL (Continued)
 (for prepn. of tetraazacyclododecanetetraacetic acid-galactose Gd(III) complex as MRI contrast agent)
 RN 185948-90-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-[2-[(2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 185948-90-7DP, Gadolinium complex
 (prepn. as MRI contrast agent)
 RN 185948-90-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-[2-[(2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl)oxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 24 OF 42 USPATFULL
 ACCESSION NUMBER: 1999:136685 USPATFULL
 TITLE: Pretargeting protocols for the enhanced localization of

cytotoxins to target sites and cytotoxic combinations useful therefore
 INVENTOR(S): Fritzberg, Alan R., Edmonds, WA, United States
 Abrams, Paul G., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 Graves, Scott S., Monroe, WA, United States
 Kasma, Sudhakar, Kirkland, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

NUMBER	KIND	DATE
US 5976535		19991102
US 1995-468513		19950606 (8)
Continuation of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5288342		


DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Cunningham, Thomas M.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
 LINE COUNT: 4278
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.
 IT 60239-18-1DP, DOTA, biotin conjugates
 (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L9 ANSWER 25 OF 42 USPATFULL
 ACCESSION NUMBER: 1999:113890 USPATFULL
 TITLE: Biotinidase resistant biotin-DOTA conjugates
 INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5955605		19990921
APPLICATION INFO.:	US 1996-695940		19960812 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-351469, filed on 21 Feb 1995, now patented, Pat. No. US 5608060		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Eisenschenk, Frank C.		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 24 Drawing Page(s)		
LINE COUNT:	4727		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof		

in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.
 IT 60239-18-1BP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 26 OF 42 USPATFULL (Continued)
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L9 ANSWER 26 OF 42 USPATFULL
 ACCESSION NUMBER: 1999:88767 USPATFULL
 TITLE: Therapeutic and diagnostic imaging compositions and methods
 INVENTOR(S): Snow, Robert A., West Chester, PA, United States
 Ladd, David L., Wayne, PA, United States
 Toner, John L., Downingtown, PA, United States
 Sterling Winthrop Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5932188		19990803
APPLICATION INFO.:	US 1997-963125		19971028 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-493523, filed on 22 Jun 1995, now abandoned which is a continuation of Ser. No. US 1994-352682, filed on 30 Nov 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose' G.		
ASSISTANT EXAMINER:	Hartley, Michael G.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1005		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB This invention provides therapeutic and diagnostic imaging compositions and methods featuring a polymer comprising units containing a poly(alkylene oxide) moiety linked to the residue of a chelating agent, said polymer having a cytotoxic agent associated therewith.

IT 60239-18-1D, DOTA, conjugates with polyalkylene oxide polymers 114873-37-9D, conjugates with polyalkylene oxide polymers (polyalkylene oxide polymer conjugates with chelating agents for therapeutic and diagnostic imaging compns. and methods)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



RN 114873-37-9 USPATFULL


L9 ANSWER 27 OF 42 USPATFULL
 ACCESSION NUMBER: 1999:69701 USPATFULL
 TITLE: Pretargeting methods and compounds
 INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 Sanderson, James A., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5914312		19990622
APPLICATION INFO.:	US 1994-297429		19940826 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Eisenschenk, Frank C.		
ASSISTANT EXAMINER:	Nolan, Patrick		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	2191		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.

IT 60239-18-1BP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 28 OF 42 USPATFULL
 ACCESSION NUMBER: 1999:66990 USPATFULL
 TITLE: Pretargeting protocols for enhanced localization of active agents to target sites
 INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Mallett, Robert W., Seattle, WA, United States
 Hyllarides, Mark D., Mukilteo, WA, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5911969		19990615
APPLICATION INFO.:	US 1994-329617		19941026 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a		


continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eiseenschek, Frank C.
 ASSISTANT EXAMINER: Nolan, Patrick J.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 2172
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are disclosed.

IT 60239-18-1DP, DOTA, biotin conjugates
 (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 30 OF 42 USPATFULL
 ACCESSION NUMBER: 1998:138472 USPATFULL
 TITLE: Dendrimeric compounds
 INVENTOR(S): Margerum, Larry, Wayne, PA, United States
 Campion, Brian, Solano Beach, CA, United States
 Fellmann, Jere Douglas, Livermore, CA, United States
 Garrity, Martha, San Clemente, CA, United States
 PATENT ASSIGNEE(S): Nycomed Salutar, Inc., Wayne, PA, United States (U.S. corporation)


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834020		19981110
APPLICATION INFO.:	WO 9528966		19951102
	US 1997-722082		19970121 (8)
	WO 1995-GB898		19950420
			19970121 PCT 371 date
			19970121 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-7812	19940420

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Levy, Neil S.
 LEGAL REPRESENTATIVE: Fish & Richardson P.C.
 NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2049
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a dendrimeric compound comprising a dendrimeric bioactive moiety with linked thereto a plurality of diagnostically or therapeutically active moieties characterized in that the molecular skeleton of said compound contains at least one biodegradable cleavage site such that on cleavage thereof said active moieties are released in renally excretable form.

IT 173308-27-5P 173308-28-6P
 (prepn. of gadolinium complexes as contrast agents)
 RN 173308-27-5 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-([2-oxo-2-([2-([1-oxooctadecyl)amino]ethyl)amino]ethyl)- (9CI) (CA INDEX NAME)



RN 173308-28-6 USPATFULL
 CN Cholest-5-en-3-ol (3.beta.)-, [2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 29 OF 42 USPATFULL
 ACCESSION NUMBER: 1998:154419 USPATFULL
 TITLE: Production of nitro-benzyl-dota via direct peptide cyclization
 INVENTOR(S): Yau, Eric K., Kirkland, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5847121		19981208
APPLICATION INFO.:	US 1995-571816		19951213 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-345811, filed on 22 Nov 1994, now patented, Pat. No. US 5541287 which is a continuation-in-part of Ser. No. US 1993-156565, filed on 22 Nov 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now		


abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Datlow, Philip I.
 LEGAL REPRESENTATIVE: Seed and Berry LLP
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1,6
 NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)
 LINE COUNT: 4337
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also disclosed.


IT 60239-18-1DP, DOTA, biotin conjugates
 (prepn. of, for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




L9 ANSWER 30 OF 42 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B



IT 149353-23-1
 (prepn. of gadolinium complexes as contrast agents)
 RN 149353-23-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, tris(1,1-dimethylethyl) ester, monohydrobromide (9CI) (CA INDEX NAME)

L9 ANSWER 30 OF 42 USPATFULL (Continued)




● HBr

IT 150467-20-2P 173308-18-4P 173308-19-5P
173308-24-2P

(prepn. of gadolinium complexes as contrast agents)

RN 150467-20-2 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 173308-18-4 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) methyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 31 OF 42 USPATFULL

ACCESSION NUMBER: 1998:79136 USPATFULL

TITLE: Chelated somatostatin **peptides** and complexes thereof, pharmaceutical compositions containing them and their use in treating tumorsINVENTOR(S): Albert, Rainer, Basel, Switzerland
Krenning, Eric P., Rotterdam, Netherlands
Lamberts, Steven W. J., Rotterdam, Netherlands
Pless, Janos, Basel, Switzerland

PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

NUMBER	KIND	DATE
US 5776894		19980707
US 1995-479052		19950606 (8)
Continuation of Ser. No. US 1994-328296, filed on 24 Oct 1994, now abandoned which is a continuation of		

Ser. No. US 1993-34336, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-709868, filed on 3 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-445815, filed on 4 Dec 1989, now abandoned

NUMBER	DATE
GB 1988-28364	19881205
GB 1989-16115	19890713
GB 1989-16761	19890721
GB 1991-11199	19910523

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Borovian, Joseph J.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1082

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Somatostatin **peptides** bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said **peptide**, and said amino group having no significant binding affinity for somatostatin receptors, in free or

salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.


IT 60239-18-1D, DOTA, reaction products with somatostatin peptide analogs, complexes with labels

(for tumor imaging and therapy)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)


L9 ANSWER 30 OF 42 USPATFULL (Continued)



RN 173308-19-5 USPATFULL


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2-aminoethyl)amino]-2-oxoethyl]-, tris(1,1-dimethylethyl) ester (9CI)

(CA INDEX NAME)




RN 173308-24-2 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[2-[(3-carboxy-1-oxopropyl)amino]ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 31 OF 42 USPATFULL (Continued)



L9 ANSWER 32 OF 42 USPATFULL
 ACCESSION NUMBER: 1998:54871 USPATFULL
 TITLE: Use of certain complexed somatostatin peptides for the in vivo imaging of somatostatin receptor-positive tumors and metastasis
 INVENTOR(S): Albert, Rainer, Basel, Switzerland
 Krenning, Eric P., Capelle, Netherlands
 Lamberts, Steven W. J., Rotterdam, Netherlands
 Pless, Janos, Basel, Switzerland
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5753627		19980519
APPLICATION INFO.:	US 1995-470099		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-328296, filed on 24 Oct 1994, now abandoned which is a continuation of Ser.		

No. US 1993-34336, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-709868, filed on 3 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-445815, filed on 4 Dec 1989, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Tsang, Cecilia J.
 ASSISTANT EXAMINER: Marshall, S. G.
 LEGAL REPRESENTATIVE: Borovian, Joseph J.
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1057

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or

salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.

IT 60239-18-1D, DOTA, reaction products with somatostatin peptide analogs, complexes with labels (for tumor imaging and therapy)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

L9 ANSWER 32 OF 42 USPATFULL (Continued)



L9 ANSWER 33 OF 42 USPATFULL
 ACCESSION NUMBER: 1998:4212 USPATFULL
 TITLE: Magnetic resonance imaging agents for the detection of physiological agents
 INVENTOR(S): Meade, Thomas, Altadena, CA, United States
 Fraser, Scott, Newport Beach, CA, United States
 Jacobs, Russell, Arcadia, CA, United States
 PATENT ASSIGNEE(S): Research Corporation Technologies, Tucson, AZ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5707605		19980113
APPLICATION INFO.:	US 1995-486968		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-460511, filed on 2 Jun 1995, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Kight, John
 ASSISTANT EXAMINER: Jones, Dameron L.
 LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert LLP, Trecartin, Richard F., Silva, Robin M.

NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)
 LINE COUNT: 1320


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to magnetic resonance imaging agents comprising a paramagnetic metal ion bound to a complex wherein said complex comprises a chelator and a blocking moiety covalently attached to said chelator which binds in at least a first coordination site of said metal ion and which is capable of interacting with a

target substance such that the exchange of water in at least said first coordination site is increased.

IT 60239-18-1, DOTA (chelator for prepn. of MRI contrast agents)


RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



IT 185948-90-7P (for prepn. of tetraazacyclododecanetetraacetic acid-galactose Gd(III) complex as MRI contrast agent)
 RN 185948-90-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-[2-[(2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl)oxy]ethyl]- (9CI) (CA INDEX NAME)


L9 ANSWER 33 OF 42 USPATFULL (Continued)

Absolute stereochemistry.



IT 185948-90-TDP, Gadolinium complex (prepn. as MRI contrast agent)
 RN 185948-90-7 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-[2-[(2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 34 OF 42 USPATFULL
 ACCESSION NUMBER: 97:88724 USPATFULL
 TITLE: In vivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
 INVENTOR(S): Benney, David F., Dallas, TX, United States
 PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., Dallas, TX, United States
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5672334		19970930
APPLICATION INFO.:	US 1993-160085		19931129 (8)
RELATED APPL. INFO.:	Continuation-in-part of Ser. No. US 1992-880660, filed on 8 May 1992, now abandoned Ser. No. Ser. No. US 1991-863595, filed on 9 Dec 1991, now patented, Pat. No. US 5214661 And a continuation-in-part of Ser. No. US 1991-642033, filed on 16 Jan 1991, now patented, Pat. No. US 5336762		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hollinden, Gary E.		
LEGAL REPRESENTATIVE:	Arnold, White & Durkee		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	53 Drawing Figure(s); 53 Drawing Page(s)		
LINE COUNT:	2220		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application concerns novel agents comprising cationic or chemically

basic metal chelators in association with hydrophilic carriers of anionic or chemically acidic saccharides, sulfatoids and glycosaminoglycans. In certain embodiments, the agents comprise metals and metal ions. Covalent and non-covalent chemical and physical means are described for stabilizing the binding of the metal chelators to the carriers. Novel non-covalently bound compositions are described which give uniquely high payloads and ratio of metal chelator to carrier, ranging from a low of about 15% metal chelator by weight, to a characteristic range of 70% to 90% metal chelator by weight. Specific embodiments are described comprising deferoxamine, ferrioxamine, iron-basic porphine, iron-triethylenetetramine, gadolinium

DTPA-lysine, gadolinium DOTA-lysine and gadolinium with basic derivatives of porphyrins, porphines, expanded porphyrins, Texaphyrins and sapphyrins as the basic or cationic metal chelators, which are in turn, bound to acidic or anionic carriers, including one or more of acidic or anionic saccharides, and including sulfated sucrose, pentosan polysulfate, dermatan sulfate, oversulfated dermatan sulfate, chondroitin sulfate, oversulfated chondroitin sulfate, heparan sulfate, beef heparin, porcine

heparin, non-anticoagulant heparins, and other native and modified acidic saccharides and glycosaminoglycans.

Also disclosed are methods of enhancing in vivo images arising from induced magnetic resonance signals, methods of enhancing in vivo images in conjunction with ultrasound or X-rays and methods of obtaining in vivo body images utilizing

L9 ANSWER 35 OF 42 USPATFULL
 ACCESSION NUMBER: 97:42628 USPATFULL
 TITLE: Two-step pretargeting methods using improved biotin-active agent conjugates
 INVENTOR(S): Reno, John M., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5630996		19970520
APPLICATION INFO.:	US 1993-122979		19930916 (8)
RELATED APPL. INFO.:	Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned ,		

each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342


DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 4768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiolabeling of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are disclosed.

IT 60239-18-1DP, DOTA, conjugate (two-step pretargeting methods using conjugate of antibody and streptavidin or avidin and conjugate of biotin and DOTA radioisotope complex for treating tumor)

RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 34 OF 42 USPATFULL (Continued)
 radioisotope containing agents. Methods of treating vascular disease are also disclosed.
 IT 60239-18-1DP, DOTA, basic or amine deriva., metal chelates, conjugates with acidic saccharides and glycosaminoglycans (metal-ion chelates with acidic saccharides and glycosaminoglycans, agent prepn., and methods of enhancing MRI imaging)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 36 OF 42 USPATFULL
 ACCESSION NUMBER: 97:36156 USPATFULL
 TITLE: Clearing agents useful in pretargeting methods
 INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
 Reno, John M., Brier, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624896		19970429
APPLICATION INFO.:	US 1995-462765		19950605 (8)
RELATED APPL. INFO.:	Continuation of Ser. No. US 1993-163184, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented,		


Pat. No. US 5283342
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 18
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 12 Drawing Page(s)
 LINE COUNT: 3943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Novel clearing agents are provided which comprise biotin analog containing clearance-directing moieties. Preferably such clearance-directing moieties endogenously contain or a rederivatized to expose galactose and/or mannose residues.

IT 60239-18-1DP, DOTA, biotin conjugates (prepn. of, for tumor pretargeting methodol.)


RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 37 OF 42 USPATFULL
 ACCESSION NUMBER: 97:18284 USPATFULL
 TITLE: Biotinidase-resistant biotin-DOTA conjugates
 INVENTOR(S): Aswerthy, Donald B., Brier, WA, United States
 Theodore, Louis J., Lynnwood, WA, United States
 Gustavson, Linda M., Seattle, WA, United States
 Reno, John M., Brier, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE
 PATENT INFORMATION: US 5608060 19970304
 WO 9325240 19931223
 APPLICATION INFO.: US 1995-351469 19950221 (8)
 WO 1993-US5406 19930607
 19950221 PCT 371 date
 19950221 PCT 102(e) date
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned, each Ser. No. US which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Eisenschenk, Frank C.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 4732
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof
 in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.
 IT 60239-18-1D, DOTA, biotin conjugates
 (biotinidase-resistant biotin-DOTA conjugates for treatment and diagnosis of cancer, (pre)targeting procedures and compns., and compd. prepn. and characterization)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 38 OF 42 USPATFULL
 ACCESSION NUMBER: 97:17886 USPATFULL
 TITLE: Directed biodistribution of radiolabelled biotin using carbohydrate polymers
 INVENTOR(S): Gustavson, Linda M., Seattle, WA, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):
 NUMBER KIND DATE
 PATENT INFORMATION: US 5607659 19970304
 APPLICATION INFO.: US 1995-482788 19950607 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-12533, filed on 2 Feb 1993, now abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Hollinden, Gary E.
 ASSISTANT EXAMINER: Chapman, Lara E.
 LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, LLP
 NUMBER OF CLAIMS: 6
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
 LINE COUNT: 1819
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides methods for directing the biodistribution of molecules that are not generally specifically excreted via the renal pathway to renal excretion. The methods employ conjugates or complexes containing a directed biodistribution molecule (DBM) and one or more bound molecules, wherein the biodistribution of the conjugate or complex is directed to renal excretion in vivo by the DBM component thereof.
 IT 60239-18-1D, DOTA, derivs., conjugates
 (conjugates for directed biodistribution of small mols. not generally excreted by renal pathway)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 37 OF 42 USPATFULL (Continued)


L9 ANSWER 39 OF 42 USPATFULL
 ACCESSION NUMBER: 97:3510 USPATFULL
 TITLE: Medical compositions
 INVENTOR(S): Bogdanov, Alexei A., Newton, MA, United States
 Brady, Thomas J., Winchester, MA, United States
 The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):

NUMBER KIND DATE
 PATENT INFORMATION: US 5593658 19970114
 APPLICATION INFO.: US 1994-250635 19940527 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-940590, filed on 4 Sep 1992, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Hollinden, Gary E.
 LEGAL REPRESENTATIVE: Fish & Richardson P.C.
 NUMBER OF CLAIMS: 32
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 14 Drawing Figure(s); 9 Drawing Page(s)
 LINE COUNT: 1331
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A biocompatible medical composition including a polymeric carrier, a protective chain linked to the polymeric carrier, and a reporter group linked to the carrier or to the carrier and the protective chain. The invention also relates to a method of treating a disease in a patient by administering to the patient a therapeutically effective amount of the composition, and may include scanning the patient using an imaging technique which can detect the reporter group to obtain a visible image of the distribution of the composition.

IT 60239-18-1D, 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, adducts with graft copolymer and platinum compd.
 114873-37-9D, 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, adducts with graft copolymer and platinum compd.
 120041-08-9D, adducts with graft copolymer and platinum compd.
 (graft copolymer-platinum compd. adduct prepn. and therapeutic use)
 RN 60239-18-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)




RN 114873-37-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (9CI) (CA INDEX NAME)

L9 ANSWER 39 OF 42 USPATFULL (Continued)



RN 120041-08-9 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,
 10-(2-hydroxypropyl)-
 (9CI) (CA INDEX NAME)



L9 ANSWER 40 OF 42 USPATFULL

ACCESSION NUMBER: 96:53043 USPATFULL

TITLE: Dense star polymer conjugates

INVENTOR(S): Tomalis, Donald A., Midland, MI, United States
 Wilson, Larry R., Beaverton, MI, United States
 Hedstrand, David M., Midland, MI, United States
 Tomlinson, Ian A., Midland, MI, United States
 Fazio, Michael J., Midland, MI, United States
 Kruper, Jr., William J., Sanford, MI, United States
 Kaplan, Donald A., Cincinnati, OH, United States
 Cheng, Roberts C., Midland, MI, United States
 Edwards, David S., Burlington, MA, United States
 Jung, Chu W., Arlington, MA, United States
 The Dow Chemical Company, Midland, MI, United States
 (U.S. corporation)

PATENT ASSIGNEE(S):

NUMBER	KIND	DATE
US 5527524		19960618
US 1993-43198		19930405 (8)

PATENT INFORMATION: US 5527524 19960618
 APPLICATION INFO.: US 1993-43198 19930405 (8)
 DISCLAIMER DATE: 20110816
 RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 1991-654851, filed on 13 Feb 1991, now patented, Pat. No. US 5338532

which

is a continuation-in-part of Ser. No. US 1989-386049, filed on 26 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-87266, filed on 18 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-897455, filed on 18 Aug 1986, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Page, Thurman K.
 LEGAL REPRESENTATIVE: Kimble, Karen L.
 NUMBER OF CLAIMS: 114
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)
 LINE COUNT: 3839

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dense star polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

IT 131934-31-1


(dense star polymers as carriers for delivery of biol. active agents)

RN 131934-31-1 USPATFULL


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, trimethyl ester
 (9CI)

(CA INDEX NAME)


L9 ANSWER 40 OF 42 USPATFULL (Continued)



IT 171409-42-0P
 (dense star polymers as carriers for delivery of biol. active agents)
 RN 171409-42-0 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,10-triacetic acid, 7-(10-carboxy-2-hydroxydecyl)-, .alpha.,.alpha.,.alpha.'-trimethyl ester (9CI) (CA INDEX NAME)



IT 171409-42-0DD, reaction products with star polyamidoamine
 (dense star polymers as carriers for delivery of biol. active agents)
 RN 171409-42-0 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,10-triacetic acid, 7-(10-carboxy-2-hydroxydecyl)-, .alpha.,.alpha.,.alpha.'-trimethyl ester (9CI) (CA INDEX NAME)




IT 114873-37-9
 (dense star polymers as carriers for delivery of biol. active agents)

L9 ANSWER 40 OF 42 USPATFULL (Continued)

RN 114873-37-9 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid (9CI) (CA INDEX NAME)



L9 ANSWER 41 OF 42 USPATFULL
 ACCESSION NUMBER: 94:70818 USPATFULL
 TITLE: Starburst conjugates
 INVENTOR(S): Tomalis, Donald A., Midland, MI, United States
 Kaplan, Donald A., Cincinnati, OH, United States
 Kruper, Jr., William J., Sanford, MI, United States
 Cheng, Roberta C., Midland, MI, United States
 Tomlinson, Ian A., Midland, MI, United States
 Fazio, Michael J., Midland, MI, United States
 Hedstrand, David M., Midland, MI, United States
 Wilson, Larry R., Beaverton, MI, United States
 PATENT ASSIGNEE(S): The Dow Chemical Company, Midland, MI, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 533532		19940816
APPLICATION INFO.:	US 1991-654851		19910213 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-386049, filed on 26 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-87266, filed on 18 Aug 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-897455, filed on 18 Aug 1986, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
LEGAL REPRESENTATIVE:	Kimbble, Karen L.		
NUMBER OF CLAIMS:	65		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	2745		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Starburst conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

IT 131934-31-1 160086-96-4
 (starburst conjugates)


RN 131934-31-1 USPATFULL
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, trimethyl ester (9CI)

(CA INDEX NAME)

L9 ANSWER 41 OF 42 USPATFULL (Continued)




L9 ANSWER 41 OF 42 USPATFULL (Continued)



RN 160086-96-4 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[3-(4-isothiocyanatophenyl)-1-oxopropyl]-, trimethyl ester (9CI) (CA INDEX NAME)



IT 160086-95-3P

(starburst conjugates)

RN 160086-95-3 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[9-carboxy-2-hydroxypropyl]-, .alpha.,.alpha.,.alpha.'-trimethyl ester (9CI) (CA INDEX NAME)

L9 ANSWER 42 OF 42 USPATFULL

ACCESSION NUMBER: 94:9678 USPATFULL
 TITLE: Biotinylated small molecules
 INVENTOR(S): Gustavson, Linda M., Seattle, WA, United States
 Srinivasan, Ananthachari, St. Charles, MO, United States
 Fritzberg, Alan R., Edmonds, WA, United States
 Reno, John M., Brier, WA, United States
 Axworthy, Donald B., Brier, WA, United States
 PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5283342		19940201
APPLICATION INFO.:	US 1992-895588		19920609 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Higel, Floyd D.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1,3		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	911		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiolabeling of biotin, as well as related compounds, are described.

IT 60239-18-1DP, DOTA, biotin conjugates
 (prepn. of. for tumor pretargeting methodol.)

RN 60239-18-1 USPATFULL

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (9CI) (CA INDEX NAME)

